AstraZeneca: positive outcome for breast cancer treatment

(CercleFinance.com) - British drugmaker AstraZeneca on Wednesday announced a positive result for a late-stage study on a potential treatment for early breast cancer.


Based on an interim analysis, an independent data monitoring committee concluded that a phase III trial on Lynparza showed "sustainable, clinically relevant treatment effect" versus placebo.

The study crossed the superiority boundary for its primary endpoint of disease-free survival, the committee noted.

The independent committee now recommends that primary analysis takes place, meaning that AstraZeneca could present the trial's full results at a forthcoming medical meeting.

The Phase III trial aimed to test the efficacy and safety of Lynparza tablets versus placebo for the treatment of patients with gBRCAm high-risk HER2-negative early breast cancer, particularly after chemotherapy.

Copyright (c) 2021 CercleFinance.com. All rights reserved.